TDO2 and neoplasm: To further investigate whether TDO2 inhibitors can inhibit tumor growth and promote anti–PD-1 efficacy, we constructed a subcutaneous tumorigenesis model in C57BL/6 mice inoculated with murine OSCC cells (4MOSC2).